10-Q/A: CIMG Faces Delisting, Soaring Losses Amid Business Pivot

CIMG Inc. reported a significant net loss and negative working capital for Q4 2025, raising substantial doubt about its going concern ability, while also facing Nasdaq delisting.

Summary

• CIMG Inc. filed a 10-Q/A to include omitted Management's Discussion and Analysis for the quarter ended December 31, 2025.
• The company reported a net loss of $19,426,273 for the three months ended December 31, 2025, a substantial increase from $1,536,249 in the prior year period.
• Revenue surged to $15,768,796 for the quarter, up from $22,853 in the same period last year, driven by new product series in Asia.
• Gross profit margin significantly declined to 0.55% from 67.73% year-over-year, primarily due to discounted Maca series sales and increased proportion of other product series.
• Operating expenses increased by 37.04% to $2,079,989, mainly due to higher labor costs and professional fees.
• A fair value variation loss of $17,502,596 was recognized from digital assets (Bitcoin).
• As of December 31, 2025, cash and cash equivalents stood at $45,356, with negative working capital of $7,493,110.
• The company holds 730 Bitcoin with a carrying amount of $63,978,821, but their value is subject to significant market volatility.
• Nasdaq issued a delisting notice on March 4, 2026, due to non-compliance with multiple listing rules, and trading was suspended on March 6, 2026; the company plans to appeal.
• Management concluded that the company's internal control over financial reporting was not effective as of December 31, 2025.
• The company completed a 1-for-20 reverse stock split effective December 5, 2025.

Sentiment

Score: 1

Explanation: StockSavvy.ai views this filing as extremely negative due to the Nasdaq delisting, severe liquidity issues, substantial net loss, and ineffective internal controls, all of which overshadow the reported revenue growth.

Positives

• Revenue experienced a massive increase to $15,768,796 for the three months ended December 31, 2025, compared to $22,853 in the prior year, indicating successful expansion into new product lines.
• The company has successfully diversified its business from specialty coffee to Asian consumer food and beverage products (Maca, Homology of Medicine and Food Series) and AI computing technology services.
• Strategic acquisitions of Shanghai Huomao, Beijing Xilin, Zhimeng, and Braincon Limited have expanded the company's product portfolio and market reach in Asia.

Negatives

• Net loss dramatically increased to $19,426,273 for the quarter, up from $1,536,249 in the prior year, primarily due to a significant fair value variation loss on digital assets and increased operating expenses.
• Gross profit margin plummeted from 67.73% to 0.55%, indicating severe pricing pressure or higher cost of goods sold, particularly from discounted Maca series products.
• The company reported a negative working capital of $7,493,110 and a cash balance of only $45,356 as of December 31, 2025, highlighting severe liquidity issues.
• Management concluded that internal control over financial reporting was not effective as of December 31, 2025, which is a significant governance and operational weakness.
• The company received a delisting notice from Nasdaq, and its common stock trading was suspended, which will negatively impact investor confidence and access to capital markets.
• Recurring losses and negative cash flows from operations since inception, with an accumulated deficit of approximately $106.67 million, raise substantial doubt about the company's ability to continue as a going concern.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for at least the next twelve months due to recurring losses, negative cash flows, and negative working capital.
• The company needs to raise additional capital immediately to fund operations, and there is no assurance that such financing will be available on acceptable terms or at all.
• The value of the company's digital assets (Bitcoin) is subject to significant market volatility and does not represent a committed or assured source of financing.
• The company's common stock has been delisted from Nasdaq and is now trading on the over-the-counter market, which may reduce liquidity and investor interest.
• The company's internal control over financial reporting was deemed ineffective, increasing the risk of financial misstatements.
• Ongoing legal proceedings, including the Kim Litigation seeking $1,041,216 and the Ex-Directors Lawsuit with a judgment of $222,062.28, pose financial and reputational risks.
• The company's operating transactions are mainly denominated in RMB, exposing it to foreign currency exchange rate risk due to RMB's non-convertibility and central government policies.

Future Outlook

The company expects to need additional capital to fund its planned operations beyond the next twelve months, despite current capital resources being sufficient for that period. Management's plans to address going concern issues include seeking additional equity or debt financing and executing its revised business strategy. There is no assurance that such financing will be available on acceptable terms or at all. The company also plans to appeal the Nasdaq delisting decision, but there is no assurance of success.

Management Comments

• "We are now expanding our sales and distribution channels in Asia to provide a wider variety of healthy foods to Asian customers. We also help our customers and distributors maximize user growth and product sales through AI computing technology."
• "Management has evaluated the Company's ability to continue as a going concern by considering its current cash resources, the value of its digital assets, and its expected operating expenses over the next twelve months. Management's plans to alleviate the conditions giving rise to substantial doubt include seeking additional funding through public or private equity financings, equity-linked instruments, or other capital-raising activities."
• "Management believes that the terms of these [related party] transactions are not materially different from those that could have been obtained from independent third parties under similar circumstances."
• "We continuously refine our artificial intelligence data-processing templates and enhance the learning capabilities of the modules to deliver more accurate intelligent services across a broad range of industries."

Industry Context

StockSavvy.ai notes that CIMG Inc.'s pivot from specialty coffee to Asian consumer health products and AI computing power services reflects a strategic attempt to capitalize on high-growth markets, particularly in China. The focus on Maca-based products and traditional Chinese medicine-guided health series aligns with increasing consumer demand for wellness and natural products in Asia. The integration of AI computing technology for marketing and sales also positions the company within the broader digital transformation trend. However, the significant decline in gross margin and the substantial net loss, despite revenue growth, suggest intense competition or operational inefficiencies in these new ventures. The delisting from Nasdaq further isolates the company from mainstream capital markets, potentially hindering its ability to compete with larger, more established players in these industries.

Comparison to Industry Standards

• The gross profit margin of 0.55% is significantly below industry averages for consumer goods and technology companies, which typically range from 20% to 60% or higher, indicating severe pricing pressure or high cost structures in CIMG's new product lines.
• The substantial net loss and negative working capital position CIMG Inc. far below the financial health standards of most publicly traded companies, especially those on major exchanges, which typically maintain positive working capital and strive for profitability.
• The ineffectiveness of internal controls over financial reporting is a critical deficiency that contrasts sharply with the robust governance standards expected of public companies, potentially impacting financial reliability and investor trust.
• The delisting from Nasdaq places CIMG Inc. in a less liquid and less transparent trading environment compared to its former peers on major exchanges, which could deter institutional investors and limit capital access.

Management Changes

Corporate Governance

Legal Proceedings

• The Kim Litigation: Mr. Sooncha Kim filed a complaint on October 3, 2024, alleging breach of a Convertible Note and Warrant Purchase Agreement, seeking specific performance and monetary damages of $1,041,216. Discovery is ongoing, and no trial date has been set.
• The Ex-Directors Lawsuit: Former directors filed a complaint on March 10, 2025, for unpaid directors' fees and expenses. A judgment by default was entered against the company on August 22, 2025, and later amended on November 21, 2025, increasing the aggregate awards to $222,062.28.

Related Party Transactions

• The company had various advances to and from related parties, primarily for settling operating and administrative expenses and financing arrangements.
• As of December 31, 2025, amounts due from related parties totaled $208,714, including loans advanced to Xilin Online (Beijing) E-commerce Co., Ltd., Shenzhen Zhimeng Qiyang Technology Co., Ltd., Shanghai Huomao Cultural Development Co., Ltd., Guizhou Zhutai Huomao Liquor Industry Co., Ltd., Zhongyan Shangyue Technology Co., Ltd., and Henan Zhongyan Shangyue Technology Co., Ltd. by various shareholders and managers.
• As of December 31, 2025, amounts due to related parties totaled $1,194,655, including loans advanced to CIMG Inc. and Wewin Technology LLC by Wenwen Yu, Dada Business Trading Co., Limited, Metaverse Intelligence Tech Ltd, YY Tech Inc., and Yanqing Chen.
• All advances from or to related parties were unsecured, non-interest bearing, and had no fixed repayment terms, which management believes are not materially different from independent third-party terms.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from potential future capital raises and performance-based share issuances. The Nasdaq delisting will severely impact liquidity and the market value of their holdings. The substantial net loss and going concern doubt pose a high risk of further value erosion.
• **Employees**: Increased personnel costs suggest continued investment in human capital, but the company's precarious financial position and going concern doubt could create job insecurity.
• **Customers**: The expansion into new product lines (Maca, Homology of Medicine and Food, AI Computing Power) aims to offer a wider variety of products and services, potentially benefiting customers in Asia. However, the company's financial instability could impact service continuity or product availability.
• **Suppliers**: Advances to suppliers and accounts payable indicate ongoing business relationships, but the company's liquidity issues could pose payment risks for suppliers.
• **Creditors**: Convertible note holders and other creditors face risks due to the company's negative working capital and going concern doubt, although new convertible notes have been issued to provide some financing.

Next Steps

• The company expects to appeal the Nasdaq Hearings Panel's decision to delist its Common Stock within the applicable 15-day period.
• Management plans to seek additional equity or debt financing to address going concern issues and fund future operations.
• The company will continue to execute its revised business strategy focusing on Asian consumer products and AI computing technology.
• The company will continue to evaluate the SaaS live-streaming system of Beijing Yingtian Huyu Technology Co., Ltd., with an implementation plan expected in 2026.
• The company will continue to review and resolve legacy obligations related to Nuzee single-serving coffee and DRIPKIT products.
• The company will continue to make determinations on performance targets for the performance-based equity awards related to the Daren Business Technology Limited acquisition, with Period I beginning April 1, 2026.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a massive net loss, negative working capital, and a critically low cash balance. The Nasdaq delisting is a major blow to investor confidence and market access. Furthermore, the ineffectiveness of internal controls over financial reporting raises serious concerns about financial transparency and reliability. While revenue growth is notable, the drastic decline in gross profit margin indicates unsustainable pricing or cost structures. The 'going concern' warning, coupled with ongoing legal challenges, presents an exceptionally high-risk profile. A seasoned investor would view these cumulative factors as overwhelmingly negative, suggesting a strong sell recommendation due to the high probability of further share price depreciation and potential for significant capital loss.

Keywords

CIMG Inc., 10-Q/A, Quarterly Report, Nasdaq Delisting, Going Concern, Net Loss, Revenue Growth, Digital Assets, Bitcoin, Maca Series, Homology of Medicine and Food Series, AI Computing Power, Internal Controls, Liquidity, Capital Raise, SEC Filing, Financial Reporting, Corporate Governance, China Market, Consumer Products